Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Meta‐Analysis of Noninferiority Randomized Controlled Trials

Proton pump inhibitors (PPIs) remain the standard treatment option for erosive esophagitis (EE) but have notable limitations due to side effects associated with long‐term use. Tegoprazan, a novel potassium‐competitive acid suppressant (P‐CAB), may provide an alternative treatment option. In this study, we aim to evaluate the healing rates of EE using tegoprazan versus PPIs, along with their respective safety profiles.

• Publication year

  2025

• Venue

  JGH Open

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jgh3.70298PMID 41229531PMCID 12602160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Efficacy and Safety of Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Meta-Analysis

  2025cited by this paper
• Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi‐Center, Randomized, Double‐Blind, Active‐Comparator Phase 4 Trial

  2024cited by this paper
• Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial

  2024cited by this paper
• Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders

  2024cited by this paper
• Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

  2024cited by this paper
• Efficacy and Safety of Potassium-Competitive Acid Blockers vs Proton Pump Inhibitors for Peptic Ulcer Disease or Postprocedural Artificial Ulcers: A Systematic Review and Meta-analysis

  2024cited by this paper
• A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases

  2024cited by this paper
• The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine

  2024cited by this paper
• Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis

  2024cited by this paper
• A Linked Electronic Medical Record-Claims Analysis of the Clinical and Economic Outcomes of Patients Coded for Erosive Esophagitis in the United States

  2023cited by this paper
• Risk factors and 26-years worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis

  2023cited by this paper
• Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients

  2022cited by this paper
• Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole

  2022cited by this paper
• Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy—A Literature Review

  2021cited by this paper
• Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders

  2021cited by this paper
• Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan

  2021cited by this paper
• ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

  2021cited by this paper
• Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers

  2020cited by this paper
• Characterization of Models for Identifying Physical and Cognitive Frailty in Older Adults With Diabetes: Systematic Review and Meta-Analysis

  2020cited by this paper
• RoB 2: a revised tool for assessing risk of bias in randomised trials

  2019influential reference
• Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis

  2019cited by this paper
• Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

  2018cited by this paper
• Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

  2018cited by this paper
• Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations

  2016cited by this paper
• Editorial: Healing Erosive Esophagitis With a Proton Pump Inhibitor: The More the Merrier?

  2012cited by this paper
• Mendeley: A free research management tool for desktop and web

  2010influential reference
• What is “quality of evidence” and why is it important to clinicians?

  2008cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics.

  2007cited by this paper
• Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.

  2000cited by this paper
• GrADE: an emerging consensus on rating quality of evidence and strength of recommendations

  year unknowncited by this paper

• The promise and pitfalls of emerging potassium-competitive acid blockers for the treatment of gastroesophageal reflux disease

  2026cites this paper